BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 30733285)

  • 1. Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity.
    Chun J; Zhang JY; Wilkins MS; Subramanian B; Riella C; Magraner JM; Alper SL; Friedman DJ; Pollak MR
    Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3712-3721. PubMed ID: 30733285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DGAT2 Inhibition Potentiates Lipid Droplet Formation To Reduce Cytotoxicity in APOL1 Kidney Risk Variants.
    Chun J; Riella CV; Chung H; Shah SS; Wang M; Magraner JM; Ribas GT; Ribas HT; Zhang JY; Alper SL; Friedman DJ; Pollak MR
    J Am Soc Nephrol; 2022 May; 33(5):889-907. PubMed ID: 35232775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOL1 risk variants cause podocytes injury through enhancing endoplasmic reticulum stress.
    Wen H; Kumar V; Lan X; Shoshtari SSM; Eng JM; Zhou X; Wang F; Wang H; Skorecki K; Xing G; Wu G; Luo H; Malhotra A; Singhal PC
    Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 29967295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein L1-Specific Antibodies Detect Endogenous APOL1 inside the Endoplasmic Reticulum and on the Plasma Membrane of Podocytes.
    Scales SJ; Gupta N; De Mazière AM; Posthuma G; Chiu CP; Pierce AA; Hötzel K; Tao J; Foreman O; Koukos G; Oltrabella F; Klumperman J; Lin W; Peterson AS
    J Am Soc Nephrol; 2020 Sep; 31(9):2044-2064. PubMed ID: 32764142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ApoL1 Overexpression Drives Variant-Independent Cytotoxicity.
    O'Toole JF; Schilling W; Kunze D; Madhavan SM; Konieczkowski M; Gu Y; Luo L; Wu Z; Bruggeman LA; Sedor JR
    J Am Soc Nephrol; 2018 Mar; 29(3):869-879. PubMed ID: 29180397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA sequencing of isolated cell populations expressing human APOL1 G2 risk variant reveals molecular correlates of sickle cell nephropathy in zebrafish podocytes.
    Bundy JL; Anderson BR; Francescatto L; Garrett ME; Soldano KL; Telen MJ; Davis EE; Ashley-Koch AE
    PLoS One; 2019; 14(6):e0217042. PubMed ID: 31158233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.
    Lan X; Jhaveri A; Cheng K; Wen H; Saleem MA; Mathieson PW; Mikulak J; Aviram S; Malhotra A; Skorecki K; Singhal PC
    Am J Physiol Renal Physiol; 2014 Aug; 307(3):F326-36. PubMed ID: 24899058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Human Podocyte Cell Model Carrying G2/G2 APOL1 High-Risk Genotype.
    Ekulu PM; Adebayo OC; Decuypere JP; Bellucci L; Elmonem MA; Nkoy AB; Mekahli D; Bussolati B; van den Heuvel LP; Arcolino FO; Levtchenko EN
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.
    Beckerman P; Bi-Karchin J; Park AS; Qiu C; Dummer PD; Soomro I; Boustany-Kari CM; Pullen SS; Miner JH; Hu CA; Rohacs T; Inoue K; Ishibe S; Saleem MA; Palmer MB; Cuervo AM; Kopp JB; Susztak K
    Nat Med; 2017 Apr; 23(4):429-438. PubMed ID: 28218918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.
    Olabisi OA; Zhang JY; VerPlank L; Zahler N; DiBartolo S; Heneghan JF; Schlöndorff JS; Suh JH; Yan P; Alper SL; Friedman DJ; Pollak MR
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):830-7. PubMed ID: 26699492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of
    Haque S; Patil G; Mishra A; Lan X; Popik W; Malhotra A; Skorecki K; Singhal PC
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28385815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exon 4-encoded sequence is a major determinant of cytotoxicity of apolipoprotein L1.
    Khatua AK; Cheatham AM; Kruzel ED; Singhal PC; Skorecki K; Popik W
    Am J Physiol Cell Physiol; 2015 Jul; 309(1):C22-37. PubMed ID: 25924622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein L1 (APOL1) renal risk variant-mediated podocyte cytotoxicity depends on African haplotype and surface expression.
    Gupta N; Waas B; Austin D; De Mazière AM; Kujala P; Stockwell AD; Li T; Yaspan BL; Klumperman J; Scales SJ
    Sci Rep; 2024 Feb; 14(1):3765. PubMed ID: 38355600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOL1 risk variants affect podocyte lipid homeostasis and energy production in focal segmental glomerulosclerosis.
    Ge M; Molina J; Ducasa GM; Mallela SK; Varona Santos J; Mitrofanova A; Kim JJ; Liu X; Sloan A; Mendez AJ; Banerjee S; Liu S; Szeto HH; Shin MK; Hoek M; Kopp JB; Fontanesi F; Merscher S; Fornoni A
    Hum Mol Genet; 2021 Apr; 30(3-4):182-197. PubMed ID: 33517446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. APOL1-G2 accelerates nephrocyte cell death by inhibiting the autophagy pathway.
    Zhu JY; Lee JG; Fu Y; van de Leemput J; Ray PE; Han Z
    Dis Model Mech; 2023 Dec; 16(12):. PubMed ID: 37969018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disrupted apolipoprotein L1-miR193a axis dedifferentiates podocytes through autophagy blockade in an APOL1 risk milieu.
    Kumar V; Ayasolla K; Jha A; Mishra A; Vashistha H; Lan X; Qayyum M; Chinnapaka S; Purohit R; Mikulak J; Saleem MA; Malhotra A; Skorecki K; Singhal PC
    Am J Physiol Cell Physiol; 2019 Aug; 317(2):C209-C225. PubMed ID: 31116585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease.
    McCarthy GM; Blasio A; Donovan OG; Schaller LB; Bock-Hughes A; Magraner JM; Suh JH; Tattersfield CF; Stillman IE; Shah SS; Zsengeller ZK; Subramanian B; Friedman DJ; Pollak MR
    Dis Model Mech; 2021 Aug; 14(8):. PubMed ID: 34350953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOL1-mediated monovalent cation transport contributes to APOL1-mediated podocytopathy in kidney disease.
    Datta S; Antonio BM; Zahler NH; Theile JW; Krafte D; Zhang H; Rosenberg PB; Chaves AB; Muoio DM; Zhang G; Silas D; Li G; Soldano K; Nystrom S; Ferreira D; Miller SE; Bain JR; Muehlbauer MJ; Ilkayeva O; Becker TC; Hohmeier HE; Newgard CB; Olabisi OA
    J Clin Invest; 2024 Jan; 134(5):. PubMed ID: 38227370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein L1 (APOL1) cation current in HEK-293 cells and in human podocytes.
    Vandorpe DH; Heneghan JF; Waitzman JS; McCarthy GM; Blasio A; Magraner JM; Donovan OG; Schaller LB; Shah SS; Subramanian B; Riella CV; Friedman DJ; Pollak MR; Alper SL
    Pflugers Arch; 2023 Mar; 475(3):323-341. PubMed ID: 36449077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of endoplasmic reticulum stress signaling rescues cytotoxicity of human apolipoprotein-L1 risk variants in Drosophila.
    Gerstner L; Chen M; Kampf LL; Milosavljevic J; Lang K; Schneider R; Hildebrandt F; Helmstädter M; Walz G; Hermle T
    Kidney Int; 2022 Jun; 101(6):1216-1231. PubMed ID: 35120995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.